Cargando…
Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer
SIMPLE SUMMARY: About one third of all breast cancers are classified as HER2-positive due to high levels of the HER2 cell surface protein. Drugs that target HER2 have been mostly successful, but this type of cancer returns at a high frequency once treatment has been completed. The high levels of HER...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230691/ https://www.ncbi.nlm.nih.gov/pubmed/34208071 http://dx.doi.org/10.3390/cancers13122922 |